Using a drug to target a specific protein to kill lung cancer cells
Targeting cytoplasmic SET oncoprotein by sphingolipid analog drugs for the induction of necroptosis to treat lung cancer
['FUNDING_R01'] · MEDICAL UNIVERSITY OF SOUTH CAROLINA · NIH-10978734
This study is looking at how a drug called FTY720, usually used for multiple sclerosis, might help treat non-small cell lung cancer by targeting a specific protein in cancer cells to help them die off.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MEDICAL UNIVERSITY OF SOUTH CAROLINA (nih funded) |
| Locations | 1 site (CHARLESTON, UNITED STATES) |
| Trial ID | NIH-10978734 on ClinicalTrials.gov |
What this research studies
This research investigates the use of a drug called FTY720, which is typically used for multiple sclerosis, to treat non-small cell lung cancer (NSCLC). The study focuses on how FTY720 can bind to a protein known as cytoplasmic SET, which is often overexpressed in lung cancer cells. By targeting this protein, the drug may activate a tumor suppressor that leads to cancer cell death through a process called necroptosis. The research will involve both laboratory experiments and animal models to assess the effectiveness of this approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have not responded to standard treatments.
Not a fit: Patients with other types of lung cancer or those who are not diagnosed with cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with non-small cell lung cancer, potentially improving survival rates.
How similar studies have performed: While the use of FTY720 in cancer treatment is a novel approach, preliminary studies have shown promising results in targeting similar pathways in cancer cells.
Where this research is happening
CHARLESTON, UNITED STATES
- MEDICAL UNIVERSITY OF SOUTH CAROLINA — CHARLESTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: OGRETMEN, BESIM — MEDICAL UNIVERSITY OF SOUTH CAROLINA
- Study coordinator: OGRETMEN, BESIM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, Breast Cancer